Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
Initial Data from Cohort 1 to be Reported in December 2024 Highlights Recently Presented Insights on Pediatric MYBPC3-associated HCM Disease Burden SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today shared updates related to its ongoing Phase 1b/2 MyPEAK-1 clinical trial of TN-201. TN-201 is being developed for the potential treatment of MYBPC3 -associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C). TN-201 gene replacement therapy is designed to increase protein levels of MyBP-C to slow or even reverse the course of disease by delivering a functional copy of the MYBPC3 gene to heart muscle cells. “The MyPEAK-1 study of TN-201 is primarily intended to establish the safety profile of
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) had its price target lowered by analysts at Chardan Capital from $20.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
TNYA
Earnings
- 5/14/24 - Beat
TNYA
Sec Filings
- 11/18/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- TNYA's page on the SEC website